Entera Bio Ltd. (ENTX)
| Market Cap | 71.10M |
| Revenue (ttm) | 365,000 |
| Net Income (ttm) | -9.98M |
| Shares Out | 23.70M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $2.98 |
| Previous Close | $3.00 |
| Change ($) | -0.02 |
| Change (%) | -0.67% |
| Day's Open | 3.02 |
| Day's Range | 2.95 - 3.09 |
| Day's Volume | 83,209 |
| 52-Week Range | 1.00 - 10.16 |
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appoint...
BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will del...
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data , Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approv al of EB613 IND for the Treatment of O steoporosis Enables I...
ENTX stock continues to sky rocket, leading investors to question halted stocks. Here's what you should know now.
Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint. According to Entera, EB613 is an ...
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business an...
Entera Bio (ENTX) stock is soaring higher on Thursday following an update from the biotech company about its osteoporosis treatment. The post ENTX Stock: 11 Things for Entera Bio Investors to Know as Sh...
Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral densi...
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2:21 ‒
BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders...
EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 EB613 Phase 2...
Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript
‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ...
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and fin...
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒
BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its mana...
Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enrollment in...
BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business a...
BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of D...
BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its manag...
‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒
‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒
Entera Bio Ltd.'s (ENTX) CEO Adam Gridley on Q1 2020 Results - Earnings Call Transcript
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒ ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through S...
Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q4 2019 Results - Earnings Call Transcript
BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the...
BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a priva...
Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q3 2019 Results - Earnings Call Transcript
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as i...
JERUSALEM and BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) stud...
Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q2 2019 Results - Earnings Call Transcript
JERUSALEM and BOSTON, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for second quarter ended June 30, 2019.
Entera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call Transcript
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collabora... [Read more...]
| Industry Biotechnology | IPO Date Jun 28, 2018 |
| CEO Adam Gridley | Employees 16 |
| Stock Exchange NASDAQ | Ticker Symbol ENTX |
Financial Performance
In 2020, Entera Bio's revenue was $365,000, an increase of 54.66% compared to the previous year's $236,000. Losses were -$9.98 million, -7.52% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for Entera Bio stock is "Buy" and the 12-month stock price forecast is 11.00.